Business
Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
Hengrui Pharma ("Hengrui") (600276.SH; 01276.HK) and Bristol Myers Squibb ("BMS") today announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide.
About this update from Bristol-myers Squibb Company
[{"type":"text","content":"Landmark collaboration leverages complementary capabilities to drive speed in early innovation and help advance medicines for patients worldwide","length":144,"tagName":"p","attribs":{}},{"type":"text","content":"Agreements include 13 programs with the potential to address significant unmet patient needs and support long‑term growth","length":121,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI and PRINCETON, N.J., May 12, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui") (600276.SH; 01276.HK) and Bristol Myers Squibb ("BMS") today announced the companies have entered into global strategic collaboration and license agreements to advance a portfolio of 13 early stage programs in oncology, hematology and immunology, with the goal of accelerating discovery and development of innovative medicines for the benefit of patients worldwide.","length":471,"tagName":"p"},{"type":"text","content":"The agreements include four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five innovative assets to be jointly discovered and developed by both companies, leveraging Hengrui's discovery engine and platform technologies across several innovative modalities. Hengrui has the option to co-develop select assets and the potential to conduct certain commercialization activities globally with BMS.","length":428,"tagName":"p"},{"type":"text","content":"Under the collaboration, BMS obtains exclusive worldwide rights to the Hengrui‑originated assets outside Chinese mainland, Hong Kong SAR, and Macau SAR (the "Hengrui Territory"), while Hengrui obtains exclusive rights to the BMS‑originated assets within the Hengrui Territory, with BMS retaining rights for the rest of the world. Hengrui will be fully responsible for early clinical development to accelerate clinical proof of concept for these programs.","length":464,"tagName":"p"},{"type":"text","content":"Aligned with the collaborative innovation strategies of both BMS and Hengrui, these agreements reflect the companies' continued focus on advancing innovative science through partnership in areas of significant unmet medical need. The collaboration brings together BMS's differentiated research and discovery strengths, global clinical development capabilities, regulatory expertise, and commercial scale with Hengrui Pharma'...